Salvage chemotherapy with a combination of irinotecan hydrochloride and mitomycin C in platinum- and paclitaxelresistant epithelial ovarian cancer: case reports

Introduction: The efficacy and toxicity of salvage chemotherapy with a combination of irinotecan hydrochloride (CPT-11) and mitomycin C (MMC) for platinum-and paclitaxel-resistant epithelial ovarian cancer are reported.

Case report: Three consecutive patients with platinum- and paclitaxel- resistant epithelial ovarian cancer were treated with 120 mg/m2 of CPT-11 (days 1 and 15) and 7 mg/m2 of MMC (days 1 and 15) every four weeks. In all three cases partial responses were achieved and overall survivals were 17 months or longer. Most of the adverse side-effects were manageable.

Conclusions: This regimen could be administered even in heavily pretreated patients with platinum- and paclitaxel- resistance. Phase I and II studies are needed to confirm the feasibility of this treatment. The efficacy of most salvage treatments for platinum- and paclitaxel-resistant epithelial ovarian cancer is disappointing, and our cases might be of interest from the perspective of treating platinum- and paclitaxel-resistant ovarian cancer.

Irinotecan; Mitomycin C; Platinum resistant; Ovarian carcinoma

[1] Blackledge G., Lawton F., Redman C.: "Response of patients in phase II studies of chemotherapy in ovarian cancer: Implications for patient treatment and the design for phase II trials". Br. Med. J., 1989, 59, 650.

[2] Ozols R.F.: "Treatment of recurrent ovarian cancer: Increasrng options-"recurrent results". J. Clin. Oncol., 1997, 15, 2177.

[3] Creemers G.J., Bolis G., Gore M., Scarfone G., Lacave A.J., Guastalla J.P. et al.: "Topotecan, an active drug in the second line treatment of epithelial ovarian cancer: Results of large European phase II study". J. Clin. Oncol., 1996, 14, 3056.

[4] Kudelka A.P., Tresukosol D., Edwards C.L., Freedman R.S., Levenback C., Chantarawiroj P. et al.: "Phase II study of intravenous topotecan as a 5-day infusion for refractory epithelial ovarian carcinoma". J. Clin. Oncol., 1996, 14, 1552.

[5] ten Bokkel Huinink W., Gore M., Carmichael J., Gordon A., Malfetano J., Hudson L et al.: "Topotecan versus paclitaxel for treatment of recurrent epithelial ovarian cancer气J. Clin. Oneal., 1997, 15, 2183.

[6] Rose P.G., Blessing J.A., Mayer A.R, Homesley H.D.: "Prolonged oral etoposide as second line therapy for platinum resistant and platinum sensitive ovarian carcinoma: A Gynecologic Oncology Group Study". J. Clin. Oneal., 1998, 16, 405.

[7] Abu-Rustum N.R., Aghajanian C., Barakat R.R.: "Salvage weekly paclitaxel in recurrent ovarian cancer". Semin. Oneal., 1997, 24 (suppl. 15), 62.

[8] Muggia EM., Hainsworth J.D., Jeffers S.: "Phase II study of liposomal doxorubicin in refractory ovarian cancer: Antitumor activity and toxicity modification by liposomal encapsulation". J. Clin Oneal., 1997, 15, 987.

[9] Silver D.F., Piver M.S.: "Gemcitabine salvage chemotherapy for patients with gynecologic malignancies of the ovary, fallopian tube, and peritoneum". Am. J. Clin. Oneal. (CCT), 1999, 22, 450.

[10] Shimizu Y., Umezawa S., Hasumi K.: "A phase II study of combined CPT-11 and mitomycin-C in platinum refractory clear cell and mucinous ovarian carcinoma". Ann. Acad. Med. Singapore, 1998, 27, 650.

[11] Sakata Y., Suzuki H., Kamataki T.: "Preventive effect of TJ-14, a kampo (Chinese Herb) medicine, on diarrhea induced by irinotecan hydrochloride". Gan To Kagaku Ryoho, 1994, 21, 1241 (in Japanese).

[12] Pignata S., Varriale E., Casella G., Iodice F., DePlacido G., Perrone F.: "A phase I study of gemcitabine and epirubicin for the treatment of platinum-resistant or refractory and advanced ovarian cancer". Ann. Oneal., 2000, 11, 613.

[13] Niimi S., Nakagawa K., Sugimoto Y., Nishio K., Fujiwara Y., Yokoyama S. et al.: "Mechanisms of cross-resistance to a camptothecin analogue (CPT-11) in a human ovarian cancer cell line selected by cisplatin". Cancer Res., 1992, 52, 328.

[14] Kano Y., Suzuki K., Akutsu M., Suda K., Inoue Y., Yoshida M. et al.: "Effects of CPT-11 in combination with other anti-cancer agents in culture". Int. J. Cancer, 1992, 50, 640.

[15] Kanzawa K., Sugimoto Y., Minato K., Kasahara K., Bungo M., Nakagawa K. et al.: "Establishment of camptothecin analogue (CPT-11)-resistant cell line of human non-small-cell lung cancer: characterization and mechanism of resistance". Cancer Res., 1990, 50, 5919.

[16] Ghamande S.A., Piver M.S.: "Role of salvage chemotherapy with topotecan and cisplatin in patients with paclitaxel- and platinumresistant recurrent ovarian or primary peritoneal cancer: A phase II pilot study". J. Surg. Oneal., 1999, 72, 162.

[17] Massad L.S., Wagley E., Winkelman L., Lincoln S., Yordan E.L, de Geest K. et al.: "Salvage mitomycin/5-fluorouracil after platinum-based therapy for women with advanced ovarian cancer and related gynecologic malignancies". Eur. J. Gynaecol. Oneal., 1994, 15, 337.

[18] Reichman B., Markman M., Hakes T., Rubin S., Jones W., Curtin J. et al.: "Mitomycin-C plus a 3-day continuous intravenous infosion of 5-fluorouracil: an inactive salvage regimen for platinumresistant ovarian carcinoma". Gynecol. Oneal., 1993, 50, 30.

[19] Coven A., O'Connell G., Rusthoven J., Mazurka J.: "Phase II study of mitomycin C and 5 fluorouracil in platinum resistant ovarian cancer". Eur. J. Gynaecol. Oneal., 1992, 13, 125.

[20] Tanaka T., Umesaki N., Ogita S.: "Camptothecin and mitomycrn combination chemotherapy on ovarian clear cell carcinoma with multiple systemic metastases". Eur. J. Gynaecol. Oneal., 2000, 21, 377.

[21] Lesesne BJ.B、Rothschild N., Erickson B., Korec S., Sisk R., Keller J. et al.: "Cancer-associated hemolytic-uremic syndrome: analysis of 85 cases from a national registry". J. Clin. Oneal., 1989, 7, 781.